V. Brunetti

First name
V.
Middle name
C.
Last name
Brunetti
Brunetti, V. C., St-Jean, A., Dell'Aniello, S., Fisher, A., H. Y. Yu, O., Bugden, S. C., et al. (2022). Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. Bmc Endocr Disord, 22, 241. http://doi.org/10.1186/s12902-022-01140-1
Brunetti, V. C., H. Y. Yu, O., Platt, R. W., & Filion, K. B. (2022). The Association of Long-Acting Insulin Analogue Use Versus Neutral Protamine Hagedorn Insulin Use With Major Adverse Cardiovascular Events Among Individuals With Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14802
Brunetti, V. C., Reynier, P., Azoulay, L., H. Y. Yu, O., Ernst, P., Platt, R. W., & Filion, K. B. (2021). SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5192
Brunetti, V. C., H. Y. Yu, O., Platt, R. W., & Filion, K. B. (2021). Initiation of four basal insulins and subsequent treatment modification in people treated for type 2 diabetes in the United Kingdom: Changes over the period 2003-2018. Diabet Med. http://doi.org/10.1111/dme.14603